• Chiao-En Wu, Yi-Hua Liao, Cheng-Lin Wu, Ruoh-Fang Yen, Chia-Chi Lin, Muh-Hwa Yang, Chueh-Chuan Yen, Wu-Chou Su, Chia-Jui Yen, Yi-Fang Chang, Ming-Fang Wu, Youngsen Yang, Chen-Yuan Lin, Wen-Chi Yang, Hui-Ching Wang, Cheng-Yuan Li, Yin-Yu Ho, Yao-Yu Chang, Chieh-Shan Wu, Hsiu-Cheng Hsu, Kuang-Hua Chen, Yenlin Huang, Chih-Jung Chen, Pei-Ju Chuang, Yung-Chi Lai, Yu-Yi Huang, Neng-Chuan Tseng, Yi-Ting Huang, Chia-Yu Chu, and Wen-Cheng ChangJohnJDivision of Hematology/Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan City, Taiwan. Electronic address: wen1902@hotmail.com..
• Division of Hematology/Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan City, Taiwan.
• J Formos Med Assoc. 2024 Jan 1; 123 (1): 7157-15.

AbstractMelanoma is rare in Taiwan. Asian melanoma is distinct from Western melanoma because acral and mucosal melanoma accounts for the majority of melanoma cases, leading to distinct tumor behaviors and genetic profiling. With consideration of the clinical guidelines in Western countries, Taiwanese experts developed a local clinical practice consensus guideline. This consensus includes diagnosis, staging, and surgical and systemic treatment, based only on clinical evidence, local epidemiology, and available resources evaluated by experts in Taiwan. This consensus emphasizes the importance of surgical management, particularly for sentinel lymph node biopsies. In addition, molecular testing for BRAF is mandatory for patients before systemic treatment. Furthermore, immunotherapy and targeted therapy are prioritized for systemic treatment. This consensus aimed to assist clinicians in Taiwan in diagnosing and treating patients according to available evidence.Copyright © 2023. Published by Elsevier B.V.

15 keywords...

hide…